The cancellation leaves hydroxychloroquine, an older malaria drug that Novartis Chief Executive Vas Narasimhan is touting as a potential coronavirus treatment, in its Sandoz generic unit’s portfolio.
Novartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India’s Aurobindo Pharma Ltd as regulators balked, setting back the Swiss drugmaker’s shift to more profitable medicines.
The cancellation leaves hydroxychloroquine, an older malaria drug that Novartis Chief Executive Vas Narasimhan is touting as a potential coronavirus treatment, in its Sandoz generic unit’s portfolio.
Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.
Novartis said the Aurobindo deal’s collapse was not coronavirus-related, from its perspective, but stemmed from the U.S. Federal Trade Commission’s not giving approval within expected timelines. The transaction was supposed to have been completed last year but was delayed repeatedly.
Narasimhan announced the transaction with India’s Aurobindo in September 2018 as he hoped to shed generics assets in the United States that have faced fierce price pressure and dragged down Sandoz’s profitability.
In 2019, the U.S. assets continued to weigh on Sandoz’s performance, as the generics division’s sales fell 1% to $9.7 billion as price erosion in the United States canceled growth elsewhere. Sales in the oral solids and skin business fell to $1.1 billion in 2019 from $1.2 billion in 2018.
Earlier this year, Novartis projected Sandoz’s sales were expected to grow at a low-single-digit rate in 2020, excluding the U.S. oral solids and dermatology businesses. The company did not immediately update guidance now that Sandoz will continue to operate the assets within its U.S. business.
Though a tiny part of Sandoz’s and other drugmakers’ portfolios, hydroxychloroquine has been subject of intense attention after U.S. President Donald Trump touted it as a potential miracle cure against COVID-19.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Severity: Warning
Message: count(): Parameter must be an array or an object that implements Countable
Filename: amp/news_details_amp.php
Line Number: 252
Backtrace:
File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler
File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view
File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.
media@smartmarketnews.com | sales@smartmarketnews.com
Contact Us